



Chris Jewell, JD, MBA  
Senior Vice President and General Counsel  
Taiho Oncology, Inc.  
101 Carnegie Center, Suite 101  
Princeton, NJ 08540

**RE: NDA 214801**  
LYTGOBI® (futibatinib) tablets, for oral use  
MA 89

Dear Chris Jewell:

The Food and Drug Administration has completed evaluation of your firm's response to our Untitled Letter dated March 21, 2025. Based on our evaluation, it appears that you have addressed the violations contained in this Untitled Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during subsequent surveillance or through other means.

If you have any questions or comments, please direct your response to the undersigned at the **Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 89 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Untitled Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.

Additionally, the response submission should be coded as an Amendment to eCTD Sequence 5088 under NDA 214801. Questions related to the submission of your response letter should be emailed to the OPDP RPM at [CDER-OPDP-RPM@fda.hhs.gov](mailto:CDER-OPDP-RPM@fda.hhs.gov).

Sincerely,

{See appended electronic signature page}

Rebecca Falter, PharmD, BCACP  
Regulatory Review Officer  
Division of Advertising & Promotion Review 1  
Office of Prescription Drug Promotion

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

REBECCA A FALTER  
05/21/2025 01:49:43 PM